CeQur to Hire 100 Employees with Facility Expansion in Marlborough

MARLBOROUGH, Mass., April 11, 2016 /PRNewswire/ -- CeQur^®, a leader in simple insulin infusion for people with diabetes, today announced that the company is doubling the size of its Marlborough facilities in preparation for the launch of PAQ^®, the company's simple, three-day insulin infusion device. When completed later this year, the Marlborough facility will total 25,000 square feet, including a new clean room, labs and a manufacturing line. CeQur anticipates the expanded space will house 150 employees - the company's 50 current employees, in addition to more than 100 employees CeQur plans to hire over the next 24 months.

"Over the past year, we've optimized PAQ for high-volume, low-cost manufacturing and continued to amass clinical evidence that demonstrate PAQ will offer a safe, simple-to-use and cost-effective alternative to daily insulin injections for people with type 2 diabetes," said Doug Lawrence, CEO of CeQur. "We are excited to be expanding our facilities here in Marlborough in preparation for the market introduction of PAQ."

There are an estimated 5 million people with type 2 diabetes in the United States. Clinical studies have demonstrated that people using PAQ to replace their multiple daily insulin injections experience significant improvement in glycemic control and high device satisfaction.¹ In addition, health-economic studies have shown that PAQ is a cost-effective alternative to insulin injection therapy for people with type 2 diabetes.^2,3

"The continued investment and expansion of companies like CeQur speaks to Massachusetts' leadership in life sciences and the medical device industry," said Massachusetts Governor Charlie Baker. "The expansion of their facility in Marlborough and creation of new job opportunities is important not only to the people of the Commonwealth, but all those who can benefit from continued advancements in treatments for diabetes around the world."

CeQur is celebrating the initiation of its facility expansion with a "wall-breaking" ceremony being held today in collaboration with the Massachusetts Life Sciences Center (MLSC) and Massachusetts Medical Device Industry Council (MassMEDIC). The wall-breaking will symbolize PAQ's ability to help break down the barriers of traditional insulin injections. Today's ceremony will also include a tour of the current facility and comments by several speakers, including MLSC President and CEO Travis McCready, Marlborough Mayor Arthur Vigeant, CeQur Chairman Eric Milledge and MassMEDIC President Thomas J. Sommer.

"Marlborough has been our U.S. base since CeQur was founded, and we've been extremely pleased with the resources available to us here, as well as the support we've received from the robust Massachusetts life-sciences and medical device community," said Lawrence. "We are confident that this is the best place to continue to build our company and capabilities."

"CeQur is a great example of the type of innovative company that helps make Massachusetts the global leader in life sciences," said Travis McCready, president and CEO of the MLSC. "The world's top 10 leading medical device companies all have a physical presence in Massachusetts, and we are pleased to see CeQur make a similar decision to invest, grow, and manufacture their products here. Their expansion will bring new jobs to Marlborough, further strengthening one of our state's fastest-growing life sciences hotspots. We look forward to being good partners with CeQur as they continue to grow in both scale and impact, improving care for people with diabetes."

About CeQur^®

CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PAQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.

CeQur was established in January 2008. The company is led by a team of highly experienced executives with backgrounds from relevant companies including Becton Dickinson, J&J, Novo Nordisk, Lilly, Abbott, Roche, and Smith & Nephew. More information can be found at www.cequr.com.

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation's most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. To learn more visit www.masslifesciences.com.

About MassMEDIC

The Massachusetts Medical Device Industry Council, an organization of 330 manufacturers, suppliers, research institutions, and academic health centers, promotes the unique interests of the Bay State's growing and vibrant medical device sector. Through a variety of programs, informational seminars, advocacy campaigns and other projects, MassMEDIC provides medical device manufacturers and suppliers with information on industry trends and regulatory policies, and creates forums that allow members to exchange ideas and information on issues affecting the industry. For more information about MassMEDIC, please contact (617) 414-1340 or visit www.massmedic.com.

Media:
Michele Parisi (CeQur)
925-429-1850 (o)
925-864-5028 (m)
mparisi@forwardhealthinc.com

Angus McQuilken (MLSC)
617-921-7749 (m)
amcquilken@masslifesciences.com

¹ Mader J., et. al. A Feasibility Study of a 3-Day Basal-Bolus Insulin Delivery Device in Individuals With Type 2 Diabetes. Diabetes Care. 37:1476-1479. May 2014.

² Henriksen O., Dall M., Warner J., Parkin C. Simple CSII Is Highly Cost Effective. American Diabetes Association 75^th Scientific Sessions. June 2015.

³ Henriksen O., Dall M., Warner J., Parkin C. Simple CSII Is Highly Cost Effective. 8th International Conference on Advanced Technologies & Treatments for Diabetes. February 2015.

Logo - http://photos.prnewswire.com/prnh/20150901/262688LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cequr-initiates-significant-facility-expansion-in-marlborough-300249037.html

SOURCE CeQur